纳入PSMA PET信息的列线图预测前列腺癌淋巴结受累的外部验证
本研究纳入437例经组织学确诊的前列腺癌患者,在根治性前列腺切除术和扩大盆腔淋巴结清扫前接受MRI和PSMA PET/CT,外部验证四种包含PSMA PET参数的淋巴结受累列线图及Briganti 2012和MSKCC列线图。Amsterdam-Brisbane-Sydney模型区分度最高(AUC 0.81),其次为Muehlematter模型1(AUC 0.79),两者校准良好但各阈值下存在轻微系统性风险高估;MSKCC和Briganti 2012模型AUC分别为0.68和0.67。作者认为外部验证确认了Muehlematter模型1和Amsterdam-Brisbane-Sydney列线图的强模型区分度、中等校准和良好临床效用,支持其作为指导临床决策工具的可靠性。
要点
- 437例中19.7%(86/437)为pN1,PSMA PET/CT检测淋巴结受累灵敏度47.7%、特异度95.4%。
- Amsterdam-Brisbane-Sydney模型AUC 0.81最高,Muehlematter模型1 AUC 0.79,两者校准良好但轻微高估风险。
- 以8%和15%为阈值,Amsterdam-Brisbane-Sydney和Muehlematter模型1分别可使15%和16%患者免于ePLND且不漏诊淋巴结受累。
核心结论
- 外部验证确认Muehlematter模型1和Amsterdam-Brisbane-Sydney列线图预测淋巴结受累具有强模型区分度、中等校准和良好临床效用,支持其作为指导临床决策工具的可靠性。
研究设计与样本
- 纳入经组织学确诊的前列腺癌患者,在根治性前列腺切除术和扩大盆腔淋巴结清扫前接受术前MRI和PSMA PET/CT,共437例。
- 外部验证四种包含PSMA PET参数的淋巴结受累列线图(三种Muehlematter模型和Amsterdam-Brisbane-Sydney模型)及Briganti 2012和MSKCC列线图。
- 对每个列线图评估模型区分度(AUC)、校准和决策曲线分析的净获益。
主要发现
- 437例中低危0.7%、中危39.8%、高危59.5%,86/437(19.7%)为pN1。
- PSMA PET/CT检测淋巴结受累的灵敏度和特异度分别为47.7%(95% CI: 36.8-58.7)和95.4%(95% CI: 92.7-97.4)。
- Amsterdam-Brisbane-Sydney模型区分度最高(AUC 0.81,95% CI: 0.76-0.86),其次为Muehlematter模型1(AUC 0.79,95% CI: 0.74-0.85),两者校准良好但各阈值下存在轻微系统性风险高估。
- MSKCC和Briganti 2012模型AUC分别为0.68(95% CI: 0.61-0.74)和0.67(95% CI: 0.61-0.73),两者校准中等。
- 决策曲线分析显示Amsterdam-Brisbane-Sydney模型在5-20%阈值范围内净获益更优,Muehlematter模型1列线图在14-20%范围内显示获益;以Amsterdam-Brisbane-Sydney列线图8%阈值和Muehlematter模型1 15%阈值,分别可使15%和16%患者免于ePLND且不漏诊淋巴结受累。
关键数值与推荐
- Amsterdam-Brisbane-Sydney模型AUC 0.81(95% CI: 0.76-0.86),校准良好但各阈值下轻微系统性高估风险。
- Muehlematter模型1 AUC 0.79(95% CI: 0.74-0.85),校准良好但各阈值下轻微系统性高估风险。
- MSKCC模型AUC 0.68(95% CI: 0.61-0.74),校准中等;Briganti 2012模型AUC 0.67(95% CI: 0.61-0.73),校准中等。
- PSMA PET/CT检测淋巴结受累灵敏度47.7%(95% CI: 36.8-58.7),特异度95.4%(95% CI: 92.7-97.4)。
- Amsterdam-Brisbane-Sydney列线图8%阈值和Muehlematter模型1 15%阈值下,分别15%和16%患者可免于ePLND且不漏诊淋巴结受累。
临床怎么用
- 作者认为外部验证结果支持Muehlematter模型1和Amsterdam-Brisbane-Sydney列线图作为指导临床决策工具的可靠性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Novel nomograms predicting lymph node involvement (LNI) of prostate cancer (PCa) including PSMA PET information have been developed. However, their predictive accuracy in external populations is still unclear. PURPOSE: To externally validate four LNI nomograms including PSMA PET parameters (three Muehlematter models and the Amsterdam-Brisbane-Sydney model) as well as the Briganti 2012 and MSKCC nomograms. METHODS: Patients with histologically confirmed PCa undergoing preoperative MRI and PSMA PET/CT before radical prostatectomy (RP) and extended pelvic lymph node dissection (ePLND) were included. Model discrimination (AUC), calibration and net benefit using decision curve analysis were determined for each nomogram. RESULTS: A total of 437 patients were included, comprising 0.7% with low-risk disease, 39.8% with intermediate-risk disease, and 59.5% with high-risk disease. Among them, 86 out of 437 (19.7%) had pN1 disease. The sensitivity and specificity of PSMA PET/CT for the detection of LNI were 47.7% (95% CI: 36.8-58.7) and 95.4% (95% CI: 92.7-97.4), respectively. Among predictive models, the Amsterdam-Brisbane-Sydney model achieved the highest discrimination (AUC: 0.81, 95% CI: 0.76-0.86), followed by Muehlematter Model 1 (AUC: 0.79, 95% CI: 0.74-0.85), both with good calibration but slight systematic overestimation of risks across all thresholds. The MSKCC and Briganti 2012 models had AUCs of 0.68 (95% CI: 0.61-0.74) and 0.67 (95% CI: 0.61-0.73), respectively, and both had moderate calibration. Decision curve analysis indicated that the Amsterdam-Brisbane-Sydney model provided superior net benefit across thresholds of 5-20%, followed by the Muehlematter Model 1 nomogram showing benefit in the 14-20% range. Using thresholds of 8% for the Amsterdam-Brisbane-Sydney nomogram and 15% for Muehlematter Model 1, ePLND could be spared in 15% and 16% of patients, respectively, without missing any LNI cases. CONCLUSION: External validation of the Muehlematter Model 1 and Amsterdam-Brisbane-Sydney nomograms for predicting LNI confirmed their strong model discrimination, moderate calibration, and good clinical utility, supporting their reliability as tools to guide clinical decision-making.
引用
- Van Bergen TD, Braat AJAT, Hermsen R, et al. External validation of nomograms including PSMA PET information for the prediction of lymph node involvement of prostate cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 40172694. doi:10.1007/s00259-025-07241-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。